This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

This study has been withdrawn prior to enrollment.
(Enrollment difficulties)
Information provided by:
HaEmek Medical Center, Israel Identifier:
First received: August 15, 2006
Last updated: September 3, 2015
Last verified: September 2015
It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Condition Intervention
Ovarian Hyperstimulation Syndrome Infertility Drugs Female Procedure: Delayed embryo transfer

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Implantation rate per transfer
  • Pregnancy rate per embryo transfer
  • Implantation rate per IVF cycle
  • Pregnancy rate per IVF cycle

Enrollment: 0

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00365027

Sponsors and Collaborators
HaEmek Medical Center, Israel
Study Chair: Eliezer Shalev HaE'mek medical center
  More Information Identifier: NCT00365027     History of Changes
Other Study ID Numbers: 5040706
Study First Received: August 15, 2006
Last Updated: September 3, 2015

Keywords provided by HaEmek Medical Center, Israel:
GNRH agonist
ovarian hyperstimulation syndrome
Embryo cryopreservation

Additional relevant MeSH terms:
Ovarian Hyperstimulation Syndrome
Genital Diseases, Male
Genital Diseases, Female
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017